MCID: CHG001
MIFTS: 66

Chagas Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 75 53 59 55 43 3 3 44 15 72 33
American Trypanosomiasis 12 75 53 59 3 17
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 53
New World Trypanosomiasis 53
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

59
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12140
ICD9CM 35 086.2
MeSH 44 D014355
SNOMED-CT 68 54570006
ICD10 via Orphanet 34 B57.0 B57.1 B57.2 more
UMLS via Orphanet 73 C0041234
Orphanet 59 ORPHA3386
UMLS 72 C0007932 C0041234

Summaries for Chagas Disease

MedlinePlus : 43 What is Chagas disease? Chagas disease, or American trypanosomiasis, is an illness that can cause serious heart and stomach problems. It is caused by a parasite. Chagas disease is common in Latin America, especially in poor, rural areas. It can also be found in the United States, most often in people who were infected before they moved to the U.S. What causes Chagas disease? Chagas disease is caused by the Trypanosoma cruzi parasite. It is usually spread by infected blood-sucking bugs called triatomine bugs. They are also known as "kissing bugs" because they often bite people's faces. When of these bugs bites you, it leaves behind infected waste. You can become infected if you rub the waste in your eyes or nose, the bite wound, or a cut. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Who is at risk for Chagas disease? Kissing bugs can be found throughout the Americas, but they are more common in certain areas. The people who are most at risk for Chagas disease Live in rural areas of Latin America Have seen the bugs, especially in those areas Have stayed in a house with a thatched roof or with walls that have cracks or crevices What are the symptoms of Chagas disease? In the beginning, there may be no symptoms. Some people do get mild symptoms, such as Fever Fatigue Body aches Headache Loss of appetite Diarrhea Vomiting A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems such as An irregular heartbeat that can cause sudden death An enlarged heart that doesn't pump blood well Problems with digestion and bowel movements An increased chance of having a stroke How is Chagas disease diagnosed? A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. What are the treatments for Chagas disease? Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with some heart complications. Can Chagas disease be prevented? There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or are staying in poor housing conditions. It is important to use insecticides to prevent bites and practice food safety. Centers for Disease Control and Prevention

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to trypanosomiasis and idiopathic achalasia, and has symptoms including fever and pruritus. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Aspirin and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and t cells, and related phenotypes are splenomegaly and hepatomegaly

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

NIH Rare Diseases : 53 Chagas disease is caused by the parasite, Trypanosoma cruzi. The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system. Chagas disease is common in Latin America, but not in the United States. The two drugs used to treat Chagas disease are nifurtimox and benznidazole. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval.

CDC : 3 Chagas disease is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis. It is estimated that as many as 8 million people living in Mexico, Central America, and South America have Chagas disease, most of whom do not know they are infected. If untreated, infection is lifelong and can be life threatening. The impact of Chagas disease is not limited to only rural areas of Latin America in which vectorborne transmission (diseases transmitted by insects) occurs. Large-scale population movements from rural to urban areas of Latin America and to other regions of the world have increased the geographic distribution and changed the epidemiology of Chagas disease. In the United States and in other regions where Chagas disease is now found but is not endemic, control strategies should focus on preventing transmission from blood transfusion, organ transplantation, and mother-to-baby (congenital transmission).

Wikipedia : 75 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 565)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 31.6 TNF TLR2 IL6 IL2 IL1B IL10
2 idiopathic achalasia 31.5 TNF NOS2 IL10
3 sleeping sickness 31.4 NOS2 IL6 IL10
4 myocarditis 31.3 TNF NPPB NOS2 IL6
5 mucocutaneous leishmaniasis 31.3 TNF IL10 CCR5
6 cutaneous leishmaniasis 31.3 TNF TLR4 TLR2 IL10 IFNG
7 exanthem 31.3 TNF IL6 IL2
8 leishmaniasis 31.2 TNF TLR4 TLR2 NOS2 IL1B IL10
9 cysticercosis 31.1 TLR4 IL6 IL1B
10 esophagitis 31.0 TGFB1 IL6 IL1B
11 cerebrovascular disease 31.0 TNF TLR4 IL6 ACE
12 schistosomiasis 31.0 TNF IL2 IL10 IFNG CCL3
13 leprosy 3 31.0 TNF TLR2 IL2 IL10 IFNG
14 autoimmune myocarditis 30.9 TNF IL6 IFNG
15 erythema multiforme 30.9 TNF IL2 IFNG
16 autoimmune disease 30.9 TNF IL6 IL2 IL1B IL10 IFNG
17 dengue hemorrhagic fever 30.8 TNF IL6 IL10 IFNG
18 peptic ulcer disease 30.8 TNF IL1B IL10
19 neuritis 30.8 TNF IL1B IFNG CCL2
20 smallpox 30.8 TNF IL2 IFNG
21 rheumatic fever 30.8 TNF IL6 IL2 IL10
22 visceral leishmaniasis 30.8 TNF TLR4 TLR2 NOS2 IL2 IL10
23 plasmodium falciparum malaria 30.7 TNF IL10 IFNG
24 endocarditis 30.7 TNF TLR2 IL6 IL10
25 uveitis 30.6 TNF IL10 IFNG CCL2
26 pertussis 30.6 TNF TLR4 IL6 IL1B IL10
27 chikungunya 30.6 TNF IL6 IL1B CCL2
28 lyme disease 30.6 TNF TLR2 IL6 IL1B
29 variola major 30.6 TLR4 IL2 IFNG CCL3
30 tetanus 30.5 IL2 IL10 IFNG
31 acute respiratory distress syndrome 30.5 TNF IL6 IL1B
32 salmonellosis 30.5 TLR4 IL1B IFNG
33 mixed connective tissue disease 30.5 TNF IL6 IL10 IFNG
34 yellow fever 30.5 IL6 CCR5 CCL2
35 posterior uveitis 30.4 TNF IL6 IL2 IFNG
36 connective tissue disease 30.4 TNF IL6 IL10 IFNG ACE
37 rheumatic heart disease 30.3 TNF TGFB1 IL6 IL10 ACE
38 cerebral palsy 30.3 TNF IL6 IL1B
39 membranous nephropathy 30.3 TNF TGFB1 ACE
40 cardiogenic shock 30.3 TNF NPPB IL6
41 end stage renal failure 30.3 TNF TGFB1 IL6 ACE
42 brucellosis 30.2 TNF TLR4 IL6 IL2 IL10 IFNG
43 echinococcosis 30.2 TNF TLR4 TLR2 IL6 IL10 IFNG
44 rubella 30.2 TNF IL10 CALR
45 typhoid fever 30.1 TNF TLR4 IL6 IL1B IFNG
46 pericarditis 30.1 TNF NPPB IL6 IL1B IFNG
47 toxoplasmosis 30.1 TNF TLR4 TLR2 IL6 IL1B IL10
48 arteriosclerosis 30.1 TLR4 IL6 IL10 CCL2 ACE
49 filariasis 30.1 TNF TLR4 TLR2 IL6 IL2 IL10
50 cytomegalovirus infection 30.0 TNF IL6 IL1B CCL3 CCL2

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
2 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
3 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
4 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
5 arrhythmia 59 32 frequent (33%) Frequent (79-30%) HP:0011675
6 thromboembolism 59 32 frequent (33%) Frequent (79-30%) HP:0001907
7 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
8 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
9 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
10 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
11 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
12 cardiomyopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001638
13 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
14 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
15 myocarditis 59 32 frequent (33%) Frequent (79-30%) HP:0012819
16 periorbital edema 59 32 frequent (33%) Frequent (79-30%) HP:0100539
17 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
18 localized skin lesion 59 32 frequent (33%) Frequent (79-30%) HP:0011355
19 autoimmune antibody positivity 59 32 frequent (33%) Frequent (79-30%) HP:0030057
20 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
21 aganglionic megacolon 59 32 occasional (7.5%) Occasional (29-5%) HP:0002251
22 achalasia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002571
23 abnormal large intestine physiology 59 32 occasional (7.5%) Occasional (29-5%) HP:0012700
24 encephalitis 59 32 very rare (1%) Very rare (<4-1%) HP:0002383
25 peripheral neuropathy 59 32 very rare (1%) Very rare (<4-1%) HP:0009830
26 edema 59 Frequent (79-30%)
27 abnormality of the nervous system 59 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1

MGI Mouse Phenotypes related to Chagas Disease:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
2 homeostasis/metabolism MP:0005376 10.44 ACE ADRB1 CALR CCR5 CD4 CYP51A1
3 growth/size/body region MP:0005378 10.43 ACE ADRB1 CALR CD4 CYP51A1 IFNG
4 immune system MP:0005387 10.4 ACE CCL2 CCR5 CD4 CYP51A1 IFNG
5 mortality/aging MP:0010768 10.38 ACE ADRB1 CALR CCR5 CD4 CYP51A1
6 cellular MP:0005384 10.37 CALR CCR5 CD4 IFNG IL10 IL2
7 hematopoietic system MP:0005397 10.36 ACE CCR5 CD4 IFNG IL10 IL1B
8 behavior/neurological MP:0005386 10.35 ACE CCR5 IFNG IL10 IL2 IL6
9 digestive/alimentary MP:0005381 10.35 CCR5 CD4 CYP51A1 IFNG IL10 IL2
10 endocrine/exocrine gland MP:0005379 10.31 ACE ADRB1 CD4 IFNG IL10 IL2
11 liver/biliary system MP:0005370 10.24 ACE CCR5 IFNG IL10 IL2 IL6
12 muscle MP:0005369 10.23 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
13 adipose tissue MP:0005375 10.21 ACE ADRB1 IL6 NOS2 TGFB1 TLR2
14 integument MP:0010771 10.21 CD4 IFNG IL10 IL1B IL6 NOS2
15 neoplasm MP:0002006 10.21 ACE CCR5 IFNG IL10 IL1B IL2
16 nervous system MP:0003631 10.18 CALR CCR5 CD4 IFNG IL10 IL1B
17 craniofacial MP:0005382 10.13 CYP51A1 IFNG IL10 IL1B NOS2 TGFB1
18 reproductive system MP:0005389 9.96 ACE CCR5 IFNG IL10 IL2 IL6
19 no phenotypic analysis MP:0003012 9.91 ADRB1 CD4 CYP51A1 IFNG IL10 IL2
20 renal/urinary system MP:0005367 9.87 ACE IFNG IL6 NOS2 TGFB1 TLR2
21 respiratory system MP:0005388 9.81 IFNG IL10 IL2 IL6 NOS2 TGFB1
22 skeleton MP:0005390 9.7 ADRB1 CYP51A1 IFNG IL10 IL1B IL6
23 vision/eye MP:0005391 9.28 CCR5 IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 102)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
4
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Enalaprilat Approved Phase 4 76420-72-9 6917719
7
Coumarin Experimental Phase 4 91-64-5 323
8 Analgesics Phase 4
9 Analgesics, Non-Narcotic Phase 4
10 Cyclooxygenase Inhibitors Phase 4
11 Fibrinolytic Agents Phase 4
12 Anti-Inflammatory Agents, Non-Steroidal Phase 4
13 Platelet Aggregation Inhibitors Phase 4
14 Anti-Inflammatory Agents Phase 4
15 Antipyretics Phase 4
16 Anticoagulants Phase 4
17 Angiotensinogen Phase 4
18 HIV Protease Inhibitors Phase 4
19
protease inhibitors Phase 4
20 Angiotensin II Type 1 Receptor Blockers Phase 4
21 Giapreza Phase 4
22 Angiotensin Receptor Antagonists Phase 4
23 Angiotensin-Converting Enzyme Inhibitors Phase 4
24 LCZ 696 Phase 4
25 Antihypertensive Agents Phase 4
26
Bisoprolol Approved Phase 3 66722-44-9 2405
27
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
28
Amiodarone Approved, Investigational Phase 3 1951-25-3 2157
29
Coal tar Approved Phase 3 8007-45-2
30
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
31 Nifurtimox Investigational Phase 3 23256-30-6
32 Melarsoprol Investigational Phase 3 494-79-1
33 Peripheral Nervous System Agents Phase 3
34 Neurotransmitter Agents Phase 3
35 Adrenergic beta-1 Receptor Antagonists Phase 3
36 Adrenergic Antagonists Phase 3
37 Adrenergic beta-Antagonists Phase 3
38 Sympatholytics Phase 3
39 Adrenergic Agents Phase 3
40 Autonomic Agents Phase 3
41 Cytochrome P-450 Enzyme Inhibitors Phase 3
42 Sodium Selenite Phase 3
43 Antioxidants Phase 3
44 Protective Agents Phase 3
45 Cytochrome P-450 CYP2D6 Inhibitors Phase 3
46 Cytochrome P-450 CYP2C9 Inhibitors Phase 3
47 Cytochrome P-450 CYP3A Inhibitors Phase 3
48 Sodium Channel Blockers Phase 3
49 Diuretics, Potassium Sparing Phase 3
50 Anti-Arrhythmia Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 75)
# Name Status NCT ID Phase Drugs
1 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
2 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship. Completed NCT01755403 Phase 4 Benznidazole
3 A Randomized Trial of the Effects of Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
4 Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia Completed NCT01678599 Phase 4 Benznidazole
5 Evaluation of Impact of the Implantation of an Anticoagulation Clinic in an University Hospital in Brazil Completed NCT01006486 Phase 4
6 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
7 A Multicenter, Prospective, Randomized, Open-label, Blinded-endpoint, Phase 4 Study to Evaluate the Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chronic Chagas' Cardiomyopathy Not yet recruiting NCT04023227 Phase 4 Sacubitril/valsartan;Enalapril
8 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
9 Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
10 Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis) Unknown status NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
11 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
12 Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial) Completed NCT02517632 Phase 3
13 Cardiac Rehabilitation Program in Patients With Chagas Heart Failure: a Pilot Study Completed NCT02516293 Phase 2, Phase 3
14 A Randomized Double-blind Placebo Force-titration Controlled Study With Bisoprolol in Patients With Chronic Heart Failure Secondary to Chagas´ Cardiomyopathy. Completed NCT00323973 Phase 3 Bisoprolol
15 Clinical Study Comparing the Nifurtimox-Eflornithine Combination With the Standard Eflornithine Regimen for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis in the Meningoencephalitic Phase Completed NCT00146627 Phase 3 Eflornithine;Nifurtimox
16 Selenium Treatment and Chagasic Cardiopathy (STCC): A Prospective Randomized Trial in Patients With Chagas Disease Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
17 A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH) Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
18 Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
19 Prospective, Single-arm, Multicentre Study, Using a Historical Control, to Evaluate the Efficacy/Safety and Population Pharmacokinetics of Benznidazole in Children With Chronic Indeterminate Chagas Disease Not yet recruiting NCT04024163 Phase 3 Benznidazole
20 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age: A Non-inferiority Randomized Controlled Trial Not yet recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
21 Multicenter Randomized Study Of Cell Therapy In Cardiopathies - Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
22 Clinical Trial Comparing the Therapeutic Combinations Melarsoprol-Nifurtimox, Melarsoprol-Eflornithine and Eflornithine-Nifurtimox in the Treatment of Gambiense Human African Trypanosomiasis in the Meningo-Encephalitic Phase Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
23 Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project Unknown status NCT03191162 Phase 2 Benznidazole
24 Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
25 Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease. Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
26 PROTOCOL FOR PHASE II CLINICAL TRIAL, RANDOMIZED AND OPEN FOR ETIOLOGICAL TREATMENT OF CHRONIC CHAGAS DISEASE WITH POSACONAZOLE AND BENZNIDAZOLE Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
27 Phase 2 Proof-of-Activity Study of Oral Posaconazole in the Treatment of Asymptomatic Chronic Chagas Disease (Phase 2, Protocol No. P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
28 The Effects of Autologous Intracoronary Stem Cell Transplantation In Patients With End-Stage Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
29 Phase 2 Randomized, Multicenter, Double-blinded Safety and Efficacy Study to Evaluate Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
30 Effect of Colchicine on Inflammation and Myocardial Fibrosis Assessed by Magnetic Resonance Imaging in Patients With Chagas' Heart Disease Recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
31 A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma. Active, not recruiting NCT00601003 Phase 2 Nifurtimox;Cyclophosphamide;Topotecan
32 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
33 Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
34 New Chemotherapy Regimens and Biomarkers for Chagas Disease Not yet recruiting NCT03981523 Phase 2 Benznidazole;Nifurtimox
35 Phase II Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant Terminated NCT01174082 Phase 2 GM-CSF
36 Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
37 Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chagas' Disease Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
38 A Phase 1 Pharmacokinetic Drug-Drug Interaction Study of Benznidazole and E1224 in Healthy Male Volunteers Completed NCT03892213 Phase 1 Benznidazole;E1224
39 Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Diseasee Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
40 Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease Completed NCT03708133 Phase 1 Nifurtimox (Lampit, BAYA2502)_Test;Nifurtimox (Lampit, BAYA2502)_Reference
41 Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease Recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
42 Effects of Physical Training on Sensitivity Baroreflex Patients Without Chagas' Heart Ventricular Systolic Dysfunction Unknown status NCT02295215
43 Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study. Unknown status NCT02099903
44 EPIcardial and Endocardial Mapping and Ablation Using Contact Force Catheter in Chagasic Patients With Sustained Ventricular Tachycardia Unknown status NCT01847378
45 Impact of The Pharmaceutical Care on the Quality of Life of Patients With Chagas Disease and Heart Failure: Randomized Clinical Trial Unknown status NCT01566617
46 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
47 Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM) Unknown status NCT02138643
48 Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous Unknown status NCT02162992
49 Abbott ESA Chagas Assay Post-Market Study Completed NCT01662362
50 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects With Chagas Disease Completed NCT02327052

Search NIH Clinical Center for Chagas Disease

Cochrane evidence based reviews: chagas disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

41
Heart, Testes, T Cells, Colon, Eye, Bone, Brain

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 11138)
# Title Authors PMID Year
1
Cultural perception of triatomine bugs and Chagas disease in Bolivia: a cross-sectional field study. 38 17
31182163 2019
2
Comparison of methodologies for detecting Trypanosoma cruzi parasites by microscopic observation of microhematocrit capillary tubes. 38 17
31271620 2019
3
Case 20-2019: A 52-Year-Old Woman with Fever and Rash after Heart Transplantation. 17
31242366 2019
4
Synthesis and characterization of potent inhibitors of Trypanosoma cruzi dihydrofolate reductase. 9 38
20452776 2010
5
Second generation analogues of the cancer drug clinical candidate tipifarnib for anti-Chagas disease drug discovery. 9 38
20429511 2010
6
Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. 9 38
20142028 2010
7
Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase. 9 38
20090473 2010
8
Trypanosoma cruzi calreticulin: a possible role in Chagas' disease autoimmunity. 9 38
19108895 2009
9
Human autoantibodies specific for neurotrophin receptors TrkA, TrkB, and TrkC protect against lethal Trypanosoma cruzi infection in mice. 9 38
18832578 2008
10
Mapping of the conserved antigenic domains shared between potato apyrase and parasite ATP diphosphohydrolases: potential application in human parasitic diseases. 9 38
18598576 2008
11
Auto-antibodies to receptor tyrosine kinases TrkA, TrkB and TrkC in patients with chronic Chagas' disease. 9 38
18410251 2008
12
The Chagas' disease parasite Trypanosoma cruzi exploits nerve growth factor receptor TrkA to infect mammalian hosts. 9 38
18005706 2007
13
Evaluation of asymptomatic patients with chronic Chagas disease through ambulatory electrocardiogram, echocardiogram and B-Type natriuretic peptide analyses. 9 38
17057935 2006
14
Development and characterization of an immobilized enzyme reactor (IMER) based on human glyceraldehyde-3-phosphate dehydrogenase for on-line enzymatic studies. 9 38
16297925 2006
15
Brain natriuretic peptide based strategy to detect left ventricular dysfunction in Chagas disease: a comparison with the conventional approach. 9 38
16023747 2006
16
Retinal dysfunction in patients with chronic Chagas' disease is associated to anti-Trypanosoma cruzi antibodies that cross-react with rhodopsin. 9 38
16423878 2006
17
Genetic diversity and kinetic properties of Trypanosoma cruzi dihydroorotate dehydrogenase isoforms. 9 38
16172019 2006
18
CYP51 from Trypanosoma cruzi: a phyla-specific residue in the B' helix defines substrate preferences of sterol 14alpha-demethylase. 9 38
16321980 2006
19
Type 1 chemokine receptor expression in Chagas' disease correlates with morbidity in cardiac patients. 9 38
16299288 2005
20
Placental alkaline phosphatase (PLAP) enzyme activity and binding to IgG in Chagas' disease. 9 38
16122790 2005
21
Brain natriuretic peptide predicts survival in Chagas' disease more effectively than atrial natriuretic peptide. 9 38
15710733 2005
22
Specific human antibodies do not inhibit Trypanosoma cruzi oligopeptidase B and cathepsin B, and immunoglobulin G enhances the activity of trypomastigote-secreted oligopeptidase B. 9 38
15784182 2005
23
[Measurement of human brain natriuretic peptide in patients with Chagas' disease]. 9 38
15761636 2005
24
Chagas' disease parasite promotes neuron survival and differentiation through TrkA nerve growth factor receptor. 9 38
15447671 2004
25
Kinetics of expression of the salivary apyrases in Triatoma infestans. 9 38
15475299 2004
26
Phenotypic and functional characteristics of CD28+ and CD28- cells from chagasic patients: distinct repertoire and cytokine expression. 9 38
15196253 2004
27
Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. 9 38
15034825 2004
28
Role of calreticulin from parasites in its interaction with vertebrate hosts. 9 38
15128045 2004
29
PDNF, a human parasite-derived mimic of neurotrophic factors, prevents caspase activation, free radical formation, and death of dopaminergic cells exposed to the Parkinsonism-inducing neurotoxin MPP+. 9 38
14597229 2003
30
Brain natriuretic peptide in Chagas' disease: further insights. 9 38
12892979 2003
31
Brain natriuretic peptide as a predictor of cardiomyopathy in Chagas' disease. 9 38
12737906 2003
32
Polyamine biosynthetic enzymes as drug targets in parasitic protozoa. 9 38
12653650 2003
33
Brain natriuretic peptide and left ventricular dysfunction in Chagas' disease. 9 38
12241721 2002
34
Analysis of the T-cell receptor beta-chain variable-region (Vbeta) repertoire in chronic human Chagas' disease. 9 38
12366778 2002
35
Chemokine receptor CCR5 polymorphisms and Chagas' disease cardiomyopathy. 9 38
11703822 2001
36
HLA and beta-myosin heavy chain do not influence susceptibility to Chagas disease cardiomyopathy. 9 38
10955954 2000
37
Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. 9 38
10904849 2000
38
Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. 9 38
10571254 1999
39
Trypanosoma cruzi has not lost its S-adenosylmethionine decarboxylase: characterization of the gene and the encoded enzyme. 9 38
9677309 1998
40
Overlapping substrate specificities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. 9 38
9531525 1998
41
Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. 9 38
9580189 1998
42
Desensitization and sequestration of human m2 muscarinic acetylcholine receptors by autoantibodies from patients with Chagas' disease. 9 38
9148906 1997
43
Chagasic patients lack CD28 expression on many of their circulating T lymphocytes. 9 38
8560201 1996
44
Trypanosoma cruzi acidic ribosomal P protein gene family. Novel P proteins encoding unusual cross-reactive epitopes. 9 38
7693813 1993
45
Suppression by Trypanosoma cruzi of T-cell receptor expression by activated human lymphocytes. 9 38
1427979 1992
46
Cloning and expression of Trypanosoma cruzi ribosomal protein P0 and epitope analysis of anti-P0 autoantibodies in Chagas' disease patients. 9 38
1377223 1992
47
A model of insect control with imperfect treatment. 38
31290728 2019
48
Appraisal of anti-protozoan activity of nitroaromatic benzenesulfonamides inhibiting carbonic anhydrases from Trypanosoma cruzi and Leishmania donovani. 38
31219348 2019
49
Glycosylation on proteins of the intestine and perimicrovillar membrane of Triatoma (Meccus) pallidipennis, under different feeding conditions. 38
29446564 2019
50
Novel Kdr mutations (K964R and A943V) in pyrethroid-resistant populations of Triatoma mazzottii and Triatoma longipennis from Mexico and detoxifying enzymes. 38
29611294 2019

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 TNF TLR4 TLR2 TGFB1 NOS2 IL6
2
Show member pathways
13.98 TNF TGFB1 NOS2 IL6 IL2 IL1B
3
Show member pathways
13.83 TNF TLR4 TGFB1 NOS2 IL6 IL2
4
Show member pathways
13.67 TNF TGFB1 IL6 IL2 IL1B IL10
5
Show member pathways
13.57 TNF TLR4 TLR2 TGFB1 IL6 IL2
6
Show member pathways
13.51 TNF TGFB1 NOS2 IL6 IL2 IL1B
7
Show member pathways
13.46 TNF TGFB1 IL6 IL2 IL1B IL10
8
Show member pathways
13.11 TNF TLR4 TLR2 TGFB1 IL6 IL1B
9
Show member pathways
13.07 TNF TGFB1 IL6 IL2 IL1B IL10
10 12.89 TGFB1 NOS2 IL6 IL2 IFNG
11
Show member pathways
12.88 TNF TLR4 TLR2 TGFB1 IL6 IL2
12
Show member pathways
12.83 TNF TLR4 IL6 IL1B IFNG
13
Show member pathways
12.77 TNF TLR4 TLR2 TGFB1 IL6 IL2
14
Show member pathways
12.76 TNF IL1B IFNG CD4 CCR5
15 12.75 TNF TLR2 IL2 IL1B IL10 IFNG
16
Show member pathways
12.75 TNF NOS2 IL6 IL2 IL1B IL10
17
Show member pathways
12.74 TNF TGFB1 IL6 IL2 IL1B IL10
18
Show member pathways
12.71 TNF IL2 IL10 IFNG CD4
19
Show member pathways
12.52 TNF IL6 IL2 IL1B IFNG CCL2
20
Show member pathways
12.51 IL6 IL2 IL10 IFNG CCR5
21
Show member pathways
12.51 TNF TLR2 IL6 IL1B IFNG CCL2
22
Show member pathways
12.49 TNF TLR4 NOS2 IL6 IL1B IFNG
23 12.48 TNF TGFB1 IL6 IL2 CALR
24
Show member pathways
12.45 TNF TGFB1 IL6 IL2 IL1B IL10
25
Show member pathways
12.45 TNF TLR4 TLR2 TGFB1 NOS2 IL1B
26
Show member pathways
12.4 TNF TLR4 TLR2 TGFB1 NOS2 IL6
27
Show member pathways
12.39 TNF TGFB1 IL6 ADRB1 ACE
28 12.39 TNF TLR4 TLR2 TGFB1 NOS2 IL6
29
Show member pathways
12.39 TNF TLR4 TLR2 NOS2 IL6 IL1B
30 12.38 TNF TLR4 TLR2 TGFB1 NOS2 IL6
31 12.37 TNF TLR4 TLR2 TGFB1
32
Show member pathways
12.37 TNF TLR2 NOS2 IL6 IL1B
33
Show member pathways
12.36 TNF IL6 IL2 IL1B IL10
34
Show member pathways
12.34 TNF TLR4 TLR2 IL6
35
Show member pathways
12.33 TLR4 TLR2 IL1B CCR5 CCL3 CCL2
36
Show member pathways
12.29 TNF TLR4 IL1B IFNG
37 12.26 TNF IL6 IL1B IL10
38
Show member pathways
12.26 TGFB1 IL6 IL2 IL1B IL10 IFNG
39
Show member pathways
12.25 TNF TLR4 TLR2 IL6 IL1B IFNG
40 12.21 TNF IL6 IL2 IL10 IFNG CD4
41 12.19 TNF IL1B IFNG CCL2
42 12.19 TNF TGFB1 NOS2 IL6 IL1B IL10
43
Show member pathways
12.18 NOS2 IL2 IL1B IFNG CD4 CCR5
44 12.17 TNF TLR4 TGFB1 NOS2 IL6 IL2
45 12.15 TNF TGFB1 IL1B IFNG
46
Show member pathways
12.14 TLR4 TLR2 IL2 IL1B
47 12.13 TGFB1 IL6 IL1B IFNG CCL3
48 12.11 TNF TGFB1 IL6 IL1B CCL2
49 12.09 TNF IL6 IL1B CCL2
50 12.07 TLR4 NOS2 IL6 IFNG

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.8 TNF TLR4 TLR2 TGFB1 CD4 CCR5
2 extracellular region GO:0005576 9.73 TNF TGFB1 NPPB IL6 IL2 IL1B
3 external side of plasma membrane GO:0009897 9.63 TNF TLR4 CD4 CCR5 CALR ACE
4 extracellular space GO:0005615 9.4 TNF TGFB1 NPPB IL6 IL2 IL1B

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TNF TLR4 TLR2 TGFB1 IL6 IL1B
2 response to organic substance GO:0010033 9.98 TNF TGFB1 IL10 CALR
3 defense response to Gram-negative bacterium GO:0050829 9.98 TLR4 NOS2 IL6 CD4
4 cellular response to interferon-gamma GO:0071346 9.98 TLR4 TLR2 NOS2 CCL3 CCL2
5 MAPK cascade GO:0000165 9.98 TNF TGFB1 IL2 IL1B CCR5 CCL3
6 positive regulation of inflammatory response GO:0050729 9.97 TNF TLR4 TLR2 IL2 CCL3
7 regulation of insulin secretion GO:0050796 9.96 TNF NOS2 IL1B IFNG
8 inflammatory response GO:0006954 9.96 TNF TLR4 TLR2 TGFB1 IL6 IL1B
9 cell chemotaxis GO:0060326 9.95 CCR5 CCL3 CCL2
10 cellular response to organic cyclic compound GO:0071407 9.95 TNF TGFB1 IL1B CCL3 CCL2
11 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.94 TNF TGFB1 IL6
12 positive regulation of JNK cascade GO:0046330 9.94 TNF TLR4 IL1B
13 neutrophil chemotaxis GO:0030593 9.94 IL1B CCL3 CCL2
14 cellular response to mechanical stimulus GO:0071260 9.94 TLR4 TGFB1 IL1B
15 chemokine-mediated signaling pathway GO:0070098 9.94 CCR5 CCL3 CCL2
16 positive regulation of T cell proliferation GO:0042102 9.94 IL6 IL2 IL1B CD4
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 IL6 IL2 IFNG
18 humoral immune response GO:0006959 9.93 TNF IL6 IFNG CCL2
19 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 TNF TLR4 TGFB1 CD4 CCL3 CCL2
20 positive regulation of tumor necrosis factor production GO:0032760 9.92 TLR4 TLR2 CCL3
21 cellular response to lipopolysaccharide GO:0071222 9.92 TNF TLR4 NOS2 IL6 IL1B IL10
22 response to hypoxia GO:0001666 9.91 TLR2 TGFB1 NOS2
23 negative regulation of fat cell differentiation GO:0045599 9.91 TNF TGFB1 IL6
24 extrinsic apoptotic signaling pathway GO:0097191 9.91 TNF TGFB1 IFNG
25 positive regulation of interferon-gamma production GO:0032729 9.91 TNF TLR4 IL2 IL1B
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 TNF TLR4 IL1B IFNG
27 monocyte chemotaxis GO:0002548 9.9 IL6 CCL3 CCL2
28 T cell differentiation GO:0030217 9.9 TGFB1 IL2 CD4
29 positive regulation of phagocytosis GO:0050766 9.89 TNF IL1B CALR
30 negative regulation of mitotic cell cycle GO:0045930 9.89 TNF TGFB1 IL10
31 positive regulation of interleukin-6 production GO:0032755 9.89 TNF TLR4 TLR2 IL6 IL1B
32 negative regulation of interleukin-6 production GO:0032715 9.88 TNF TLR4 IL10
33 response to estradiol GO:0032355 9.88 TGFB1 CD4 CALR
34 positive regulation of interleukin-8 production GO:0032757 9.88 TNF TLR4 TLR2 IL1B
35 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.88 TNF TLR4 TLR2 IL1B CALR
36 positive regulation of protein complex assembly GO:0031334 9.86 TNF TGFB1 IFNG
37 positive regulation of interleukin-12 production GO:0032735 9.86 TLR4 TLR2 IFNG
38 negative regulation of neurogenesis GO:0050768 9.86 TNF IL6 IL1B
39 positive regulation of glial cell proliferation GO:0060252 9.85 TNF IL6 IL1B
40 regulation of regulatory T cell differentiation GO:0045589 9.84 TGFB1 IL2 IFNG
41 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.84 TNF IL1B IFNG
42 response to glucocorticoid GO:0051384 9.83 TNF IL6 IL10
43 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 TNF IL1B IL10
44 positive regulation of chemokine production GO:0032722 9.83 TNF TLR4 TLR2 IL6
45 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 TLR4 TLR2 CCL2
46 negative regulation of interleukin-17 production GO:0032700 9.8 TLR4 TGFB1 IFNG
47 cell activation GO:0001775 9.8 TLR2 TGFB1 CCL3
48 protein kinase B signaling GO:0043491 9.8 TNF TGFB1 IL1B CCL3 CCL2
49 response to cholesterol GO:0070723 9.79 TGFB1 CCR5 CCL3
50 response to molecule of bacterial origin GO:0002237 9.77 TLR2 IL10

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.56 TLR4 NPPB CD4 CCL2
2 growth factor activity GO:0008083 9.46 TGFB1 IL6 IL2 IL10
3 cytokine activity GO:0005125 9.28 TNF TGFB1 IL6 IL2 IL1B IL10
4 lipopolysaccharide receptor activity GO:0001875 8.96 TLR4 TLR2
5 protein binding GO:0005515 10.25 TNF TLR4 TLR2 TGFB1 NPPB NOS2

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....